Dover has entered into a definitive agreement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will expand Dover’s biopharma single-use production offering, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income through the full yr 2022.
When the deal closes, Malema will become a half of the PSG business unit within Dover’s Pumps & Process Solutions segment.
“We see a tremendous long-term growth alternative in the bioprocessing business driven by a robust and rising pipeline of effective novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, เกจวัดแรงดันไอน้ำ rising adoption of extra efficient single-use manufacturing processes supports a robust outlook for our offerings of single-use parts to end-customers. We believe that pairing Malema’s expertise with our present portfolio of single-use pumps for biopharma processing will significantly enhance the accuracy and value proposition of our solutions to our prospects.”
“We are methodically building out our biopharma platform through proactive capability additions, new product improvement, and opportunistic acquisitions of highly-attractive niche part technologies,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary expertise. In addition to enticing biopharma purposes, we expect strong growth within the semiconductor house on the capacity growth and re-shoring tailwinds.”
Share